Most effective VS least effective DMP* | Incremental costs | Incremental QALYs | Mean ICER | % of 5000 simulated ICERs per quadrant in the CE plane | ||||
---|---|---|---|---|---|---|---|---|
NW | NE | SW | SE | |||||
Health care perspective | ||||||||
CVR-primary# | 7 VS 4 | −534 | 0.003 | −178,539 | 1 | 3 | 41 | 56 |
(297) | (0.021) | |||||||
CVR-secondary$ | 1 VS 3 | −671 | 0.012 | −56,809 | 6 | 21 | 15 | 58 |
(976) | (0.015) | |||||||
CVR-both | 2 VS 8 | −721 | 0.005 | −148,480 | 2 | 2 | 35 | 61 |
(416) | (0.016) | |||||||
COPD | 1 VS 4 | 1,716 | 0.009 | 185,747 | 33 | 46 | 11 | 10 |
(2,000) | (0.053) | |||||||
DMII | 1 VS 3 | −677 | 0.013 | −50,234 | 1 | 3 | 14 | 82 |
(398) | (0.013) | |||||||
Societal perspective | ||||||||
CVR-primary# | 7 VS 4 | −1,131 | 0.003 | −377,991 | 5 | 12 | 37 | 46 |
(1,334) | (0.021) | |||||||
CVR-secondary$ | 1 VS 3 | −153 | 0.012 | −12,929 | 10 | 36 | 11 | 43 |
(1,225) | (0.015) | |||||||
CVR-both | 2 VS 8 | −604 | 0.005 | −124,457 | 6 | 8 | 31 | 55 |
(554) | (0.016) | |||||||
COPD | 1 VS 4 | 2,054 | 0.009 | −222,314 | 34 | 47 | 11 | 9 |
(2,371) | (0.053) | |||||||
DMII | 1 VS 3 | −1,735 | 0.013 | −128,790 | 1 | 2 | 14 | 83 |
(1,084) | (0.013) |